ITGBL1 is a new immunomodulator that favors development of melanoma tumors by inhibiting natural killer cells cytotoxicity by cheli, yann et al.
LETTER TO THE EDITOR Open Access
ITGBL1 is a new immunomodulator that
favors development of melanoma tumors
by inhibiting natural killer cells cytotoxicity
Yann Cheli1* , Meri K. Tulic2, Najla El Hachem3, Nicolas Nottet1, Arnaud Jacquel4, Maeva Gesson5, Thomas Strub1,
Karine Bille1, Alexandra Picard-Gauci6, Henri Montaudié6, Guillaume E. Beranger1,2, Thierry Passeron2,6, Pierre Close3,
Corine Bertolotto1† and Robert Ballotti1†
Abstract
Resistances to immunotherapies remains a major hurdle towards a cure for melanoma in numerous patients. An
increase in the mesenchymal phenotype and a loss of differentiation have been clearly associated with resistance
to targeted therapies. Similar phenotypes have been more recently also linked to resistance to immune checkpoint
therapies. We demonstrated here that the loss of MIcrophthalmia associated Transcription Factor (MITF), a pivotal
player in melanocyte differentiation, favors the escape of melanoma cells from the immune system. We identified
Integrin beta-like protein 1 (ITGBL1), a secreted protein, upregulated in anti-PD1 resistant patients and in MITFlow
melanoma cells, as the key immunomodulator. ITGBL1 inhibited immune cell cytotoxicity against melanoma cells
by inhibiting NK cells cytotoxicity and counteracting beneficial effects of anti-PD1 treatment, both in vitro and
in vivo. Mechanistically, MITF inhibited RUNX2, an activator of ITGBL1 transcription. Interestingly, VitaminD3, an
inhibitor of RUNX2, improved melanoma cells to death by immune cells. In conclusion, our data suggest that
inhibition of ITGBL1 might improve melanoma response to immunotherapies.
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Despite recent therapeutic improvements, the prognosis
of patients with metastatic melanoma is still very pejora-
tive. Targeted therapies (TT) using BRAF in combin-
ation with MEK inhibitors, have shown very high
response rates. However, quasi systematic acquired resis-
tances have limited the improvement of patient survival
[1]. Immuno-therapeutic approaches targeting negative
immune check points (ICT) brought stunning improve-
ment in patient survival. However, most patients are re-
sistant or develop resistance to ICT, highlighting the
need of new complementary therapeutic approaches to
overcome these resistances.
Genetic events, including mutations that cause resist-
ance to TT or ICT have been extensively described.
However, the main cause of resistance to TT is non-
genetic. It implies a rewiring of the transcriptional pro-
gram allowing the adaptation of melanoma cells to
stressful conditions imposed by the micro-environment
or by the treatment itself. Despite the diversity of non-
genetic mechanisms of resistance, loss of MITF, loss of
differentiation, as well as implementation of a pseudo-
EMT and inflammatory phenotype [2] are central to re-
sistance to TT [3]. More recently, such de-differentiated
profile has been also associated with resistance to ICT
[4].
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MITF inhibition decreases the cytotoxicity of
immune cells through the secretion of ITGBL1
MITF silencing with 2 different MITF siRNA, caused a
2-fold decrease in 501Mel cells death induced by acti-
vated PBMCs (Fig. 1a). These effects can be ascribed ei-
ther to the inhibition of the intrinsic ability of melanoma
cells to be killed by immune cells, or to decreased cyto-
toxic function of immune cells mediated by the secretion
of immunomodulating agents. When PBMCs were first
incubated with conditioned medium (CM) from siCtl or
siMITF treated 501Mel, we observed that CM from
siMITF transfected cells significantly decreased the cyto-
toxicity of PBMCs on untreated melanoma cells (Fig.
1b). This result indicates that melanoma cells secrete
negative immunomodulating agents whose secretion is
increased upon MITF silencing. MITF low cells are
known to have a pro-inflammatory secretory profile
characterized by the production of numerous cytokines
and immune regulators. To identify key secreted factors
that might impact the immune system, we integrated the
transcriptomic profile of melanoma cell lines (CCLE
Broad) expressing low MITF versus high MITF with the
genes up regulated in non-responder to immune therap-
ies [5]. We identified 40 genes that are up regulated in
both conditions (sup. fig. 1A). Among these genes, 17
were described to encode secreted proteins that might
affect the capacity of immune cells to kill melanoma
cells (sup. fig. 1B).
Among these proteins, ITGBL1 was previously re-
ported to be a bad prognosis factor in several cancer
such as gastric, ovarian, lung and colorectal cancers [6–
9]. First, we demonstrated that MITF silencing in
501Mel cells increased ITGBL1 expression (Fig. 1c) con-
firming that ITGBL1 was negatively modulated by
MITF. This was also observed in WM3912 cells (sup.
fig. 1C). The key role of secreted ITGBL1 in the inhib-
ition of immune cell cytotoxicity was demonstrated by
showing that the CM from SKMEL28 over expressing
ITGBL1 decreased the cytotoxicity of PBMCs towards
naive 501Mel melanoma cells. The cytotoxicity of
PBMCs was rescued by immuno-depletion of ITGBL1
(sup. fig. 1D, E). Next, we showed that treatment of acti-
vated PBMCs with recombinant ITGBL1 decreased their
ability to kill 501Mel melanoma cells (Fig. 1d).
Fig. 1 MITF expression modulates immune system response through a soluble, secreted factor ITGBL1 via RUNX2. a Melanoma cells were
transfected with siRNA control or 2 different siRNA directed against MITF. Forty-eight hours later, activated PBMCs were added to cells and
acquisition using Incucyte was performed. Quantification of melanoma cells death is displayed for each condition. b Activated PBMCs were
incubated for 48 h in conditioned media from siCtl or siMITF melanoma cells and subsequently incubated with naïve 501Mel melanoma cells.
Quantification of melanoma cell death after incubation with PBMCs is shown. All graphs represent mean+/−SD of 3 independent experiments. c
501Mel were transfected with two different siRNA for MITF (A) for 48 h. Protein lysates were separated by SDS page and blotted for MITF and
ITGBL1 expression. HSP90 was used as a loading control. d Resting or activated PBMCs were incubated for 48 h in presence or absence of
recombinant ITGBL1 (5 ng/ml). PBMCs were subsequently added to 501Mel melanoma cells and cell death was analyzed with Incucyte.
Quantification of melanoma cell death is displayed as the mean+/−SD of 3 independent experiments. e WM3912 melanoma cells were
transfected with control or MITF siRNA or infected with control or MITF adenoviruses. Proteins were probed for MITF and RUNX2 proteins
expression. ERK2 was used as loading control. f 501Mel cells were infected with 2 different RUNX2 shRNA (sh#1, sh#2) encoding lentiviruses or its
control shRNA (shScr). Proteins were probed for MITF and RUNX2 expression. ERK2 was used as a loading control. g 501Mel cell death was
monitored with Incucyte experiments in presence of resting or activated PBMCs. Quantification of melanoma cell death is displayed as the
mean+/−SD of 3 independent experiments. h WM9 melanoma cells were treated with 5 μM of VitD3 for 24 h, then RUNX2 and MITF proteins
analyzed by western blot. ERK2 was used as loading control. i WM9 melanoma pretreated with 5 μM VitD3 were incubated with resting or
activated PBMCs. Melanoma cell death was quantified using Incucyte. Results show as mean+/−SD of one representative experiment done
in triplicate
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Furthermore, increased GZMB and IFNγ mRNA expres-
sion upon activation of PBMCs with PMA/ionomycin
was abrogated by rITBL1 (sup. fig. 2A). Taken together
these observations support an inhibition of immune cell
activation by rITGBL1.
To gain insight on the mechanism by which MITF
regulated ITGBL1, we focused our attention on
RUNX2 that was reported to regulate ITGBL1 expres-
sion in breast cancer cells [10]. Analysis of the TCGA
melanoma database revealed a significant increase in
ITGBL1 expression in tumors with high RUNX2 ex-
pression, whereas MITF was decreased in these same
patients (sup. fig. 2B) suggesting that in melanoma
cells, ITGBL1 is positively regulated by RUNX2 and
negatively regulated by MITF. Next, the epistatic
interaction between MITF and RUNX2 was demon-
strated using siRNA approach to silence MITF or
adenoviral overexpression of MITF in WM3912 (Fig.
1e) or in 501Mel cells (sup. fig. 2C, D). In both cell
lines, while inhibition of MITF led to an increase in
RUNX2, MITF overexpression lead to a dramatic de-
crease in RUNX2 expression at protein and mRNA
level. The binding of MITF in the vicinity of RUNX2
gene as confirmed by analysis of public MITF ChIP-
Seq data [11] (sup. fig. 2E).
Next, we showed that ITGBL1 expression was dampen
upon RUNX2 silencing in 501Mel melanoma cells (sh#1,
sh#2) compare to control (shScr) (Fig. 1f). In the same
conditions, RUNX2 silencing increased melanoma cell
death mediated by PBMCs compared to control cells
(Fig. 1g).
Finally, we evaluated the effect of the treatment of
melanoma cells with Vit D3, which has been shown to
inhibit RUNX2 expression [12], on the expression of
ITGBL1 and on the PBMCs cytotoxic activity. For this
purpose, we pretreated WM9 or 501Mel melanoma cells
with VitD3 (Fig. 1h, sup. fig. 2f) and confirmed the de-
crease in ITGBL1 and RUNX2. Exposure of PBMCs to
vitamin D3-treated melanoma cells increased cytotoxic
activity of PBMCs in both resting and activated PBMCs
(Fig. 1i, sup. fig. 2f). Together, these data thus suggest
that Vit D3 might potentiate immune-mediated melan-
oma cell death by repressing RUNX2 and ITGBL1
expression.
ITGBL1 inhibits NK cells cytotoxicity towards
melanoma cells
To confirm ITGBL1 effect in vivo, we engineered
B16F10 cells over-expressing ITGBL1. Subcutaneous in-
jection of parental of ITGBL1 overexpressing B16F10 in
Fig. 2 ITGBL1 modulates tumor growth by inhibiting natural killer. a 0.15 × 106 B16F10 cells overexpressing or not ITGBL1 were injected
subcutaneously in C57BL/6 J, and tumor weight was monitored after 12 days (mean tumor weight in g ± s.e.m.). Picture of representative tumors
at 12 days is shown on the top (n = 6 mice, *P < 0.05). B) mRNA form tumor overexpressing ITGBL1 (ITGBL1) or not (Ctl) were quantified for IFNγ
and GZMB by QPCR and expressed as relative quantification in fold change. b 0.15 × 106 B16F10 cells overexpressing or not ITGBL1 were injected
subcutaneously in Nude mice and tumor volume was monitored for 15 days (mean tumor volume in g ± s.e.m.). Picture of representative tumors
at 15 days is shown on the top (n = 6 mice, *P < 0.05). c 0.15 × 106 BP cells overexpressing (ITGBL1) or not ITGBL1(Ctl) were injected
subcutaneously in C57BL/6 J. When tumor reached 50mm3, mice were treated with anti-PD1 (PD1) and tumor growth was monitored. Tumor
volume is displayed (mean tumor volume in mm3 ± s.e.m.). (n = 6 mice, *P < 0.05). d 0.15 × 106 BP cells overexpressing or not ITGBL1 were
injected subcutaneously in NSG, and tumor growth was monitored for 14 days (mean tumor volume in mm3 ± s.e.m.). Picture of representative
tumors at 14 days is shown on the top (n = 6 mice). e NK-92 cells were activated (PMA/iono) for 1 h in presence or absence of ITGBL1 (10 ng/ml).
mRNA was extracted and analyzed by QPCR for IFNγ expression. Results shown are mean+/−SD of 3 independent experiments (left panel). IFNγ
secretion in activated NK-92 cells incubated for 6 h with or without ITGBL1. Results shown are mean+/−SD (right panel). f Red stained Skmel-28
cells, overexpressing ITGBL1 or not, were cocultured with NK at ratio 1 NK/1 melanoma and treated with anti-PD1 (5 μg/ml) or its isotype control
for 24 h. Cells were analyzed by FACS with dapi and % of melanoma positive for dapi was quantified and expressed as % of melanoma death
(mean+/−SD, n = 3, *P < 0.05, **P < 0.001)
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C57BL/6 J mice showed a 2-fold increase in the weight
of tumors with ITGBL1 overexpressing B16 cells com-
pared to parental cells (Fig. 2a). QPCR assays indicated
that ITGBL1 overexpressing tumors had a decrease in
IFNγ and GZMB mRNA level (sup. fig. 3A). Then, we
performed similar experiments using athymic nude mice
that lack mature functional T cells but have more NK
cells [13]. Tumors from B16F10 cells overexpressing
ITGBL1 developed faster compared to B16F10 control
cells (Fig. 2b). With ITGBL1 overexpressing B16 cells,
tumor volume at day fifteen presented a three-fold in-
crease compared to parental cells and showed a decrease
in IFNγ and GZMB mRNA (sup. fig. 3B) confirming de-
creased immune cell activity. These results indicated
that ITGBL1 did not act on immune T-cells.
To confirm these results, we performed similar experi-
ment with of BP melanoma cells that are much more
immunogenic than B16 cells and tested the effect of
ITGBL1 in the context of anti-PD1. As expected, treat-
ment with anti-PD1, decreased parental BP tumor
growth compared to control Ig (Fig. 2c). When using BP
overexpressing ITGBL1, tumors developed faster than
parental BP tumors. In this case also, anti-PD1 treat-
ment decreased tumor growth, but ITGBL1 overexpress-
ing tumors grew significantly faster than parental
tumors submitted to the same treatment, indicating that
ITGBL1 dampen the beneficial effect of anti-PD1.
To further evaluate the involvement of the immune
system in the effect evoked by ITGBL1 overexpression,
we used NSG mice that lack T, B and NK cells. In this
case, tumors from control and ITGBL1 overexpressing
BP cells had grown at the same rate (Fig. 2d), suggesting
that ITGBL1 inhibited mainly the NK cell activity to
favor growth of melanoma tumors.
To confirm this hypothesis, we used the NK-92 cell
line and showed that rITGBL1 decreased the IFNγ
mRNA expression and secretion by two-fold (Fig. 2e) in
stimulated NK cells. Using SKMEL28 overexpressing
ITGBL1, we observed that ITGBL1 overexpressing cells
are less sensitive to cell death by NK-92 with greater
than two-fold decrease in cell death in all the conditions
(Fig. 2f, sup. fig. 4A). Furthermore, although anti-PD1
treatment slightly increased the cytotoxicity of NK-92, it
did not rescue the inhibition evoked by ITGBL1 overex-
pression. The effect of ITGBL1 on NK cells was further
confirmed, using CD56 sorted NK cells from a healthy
donor (sup. fig. 4B)
Finally, to confirm that indeed, ITGBL1 is regulated by
MITF, we modulated MITF expression in melanoma
cells with different genetic background (NRAS mutated,
BRAF/NRAS WT) and used melanoma cells with no
MITF. These experiments have demonstrated that
modulation of MITF regulates RUNX2 and ITGBL1
(sup. fig. 5). Importantly, we have shown that cells
expressing low MITF and high ITGBL1 are protected
from death following exposure to NK-92 cells whilst loss
of ITGBL1, evoked by MITF forced expression, in-
creased cells death by the same NK cells.
We also investigated the role of beta-catenin, an up-
stream regulator of MITF and RUNX2. In 501Mel cells,
known to have a β-catenin activating mutation, we con-
firmed a high LEF/TCF activity in 501Mel compared to
A375. As expected, WNT3a activated the LEF/TCF lu-
ciferase reporter in A375 cells, but not in 501Mel cells
(sup. fig. 6a). In A375, activation of β-catenin pathway
by WNT3a led to increased RUNX2 and ITGBL1 but
failed to increase MITF expression. When WNT3a-
treated A375 cells were exposed to NK92 cells, we ob-
served a decrease in cell death caused by NK cells (sup.
fig. 6b). Therefore, it seems that the WNT pathway
could regulates RUNX2, ITGBL1 and susceptibility to
NK cells induced death, independently of MITF.
Our results have identified ITGBL1 as a new immuno-
modulator secreted by melanoma cells. ITGBL1 inhibits
immune cell-mediated destruction of melanoma cells
through the modulation of tumoral innate immune sys-
tem and the decrease in NK cell activity. Importantly,
studies in immunocompetent mouse model, shows that
ITGBL1 impairs the anti-tumor effect of anti-PD1, sug-
gesting that ITGBL1 might be key player in the resist-
ance to ICT. At a mechanistic point of view, MITF
represses RUNX2 which is strong transcriptional activa-
tor of ITGBL1. Interestingly, vitamin D3, a RUNX2 in-
hibitor, that have already shown to have a positive effect
on the innate immune system [14], decreases ITGBL1
expression and markedly improves immune-mediated
death of melanoma cells, encourage future research to
evaluate the effect of Vit D3 supplementation during
immuno-therapy treatment in patients with melanoma.
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